Sagimet Biosciences Reports Positive Phase 3 Acne Data

Sagimet Biosciences, Inc. Class A ( (SGMT) ) has shared an announcement.

On February 2, 2026, Sagimet Biosciences reported that its Chinese license partner Ascletis Pharma released positive topline data from a 52-week Phase 3 program of denifanstat (ASC40) in patients with moderate to severe acne, including an open-label extension trial evaluating long-term safety. In the multi-center ASC40-304 study, 240 patients who had completed a prior 12-week randomized Phase 3 trial received once-daily oral denifanstat 50 mg for up to 40 additional weeks; treatment was generally well tolerated, with only mild to moderate treatment-related adverse events, low rates of common side effects such as dry eye and dry skin, no denifanstat-related serious adverse events, and no permanent discontinuations attributed to the drug. Patients experienced further improvements across all key efficacy measures—including Investigator’s Global Assessment response rates and reductions in total and inflammatory lesion counts—beyond those seen at 12 weeks, strengthening the clinical case for FASN inhibition as a novel mechanism in acne and supporting Sagimet’s broader strategy to advance denifanstat and next-generation FASN inhibitors across dermatologic and metabolic indications.

The most recent analyst rating on (SGMT) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Sagimet Biosciences, Inc. Class A stock, see the SGMT Stock Forecast page.

Spark’s Take on SGMT Stock

According to Spark, TipRanks’ AI Analyst, SGMT is a Neutral.

The score is primarily held down by weak financial performance (no sustained revenue, widening losses, and significant cash burn) and bearish technicals (price below key moving averages with negative MACD). Positive corporate developments in the MASH/acne pipeline and partnering provide some offset, but valuation remains constrained by ongoing losses and no dividend support.

To see Spark’s full report on SGMT stock, click here.

More about Sagimet Biosciences, Inc. Class A

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors to target dysfunctional metabolic and fibrotic pathways, including conditions driven by overproduction of the fatty acid palmitate. Its lead oral, once-daily FASN inhibitor denifanstat is being developed by Sagimet for metabolic dysfunction-associated steatohepatitis (MASH) outside China and by license partner Ascletis for moderate to severe acne in China, while a second FASN inhibitor, TVB-3567, is in early-stage development for acne.

Average Trading Volume: 605,954

Technical Sentiment Signal: Hold

Current Market Cap: $175.8M

For a thorough assessment of SGMT stock, go to TipRanks’ Stock Analysis page.